Prosecution Insights
Last updated: April 19, 2026
Application No. 16/625,877

KIT FOR EVALUATING GENE MUTATION RELATED TO MYELOPROLIFERATIVE TUMOR

Non-Final OA §112
Filed
Dec 23, 2019
Examiner
SALMON, KATHERINE D
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Yamaguchi University
OA Round
8 (Non-Final)
42%
Grant Probability
Moderate
8-9
OA Rounds
3y 11m
To Grant
80%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allow Rate
329 granted / 776 resolved
-17.6% vs TC avg
Strong +38% interview lift
Without
With
+38.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
105 currently pending
Career history
881
Total Applications
across all art units

Statute-Specific Performance

§101
18.3%
-21.7% vs TC avg
§103
27.9%
-12.1% vs TC avg
§102
13.2%
-26.8% vs TC avg
§112
33.7%
-6.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 776 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/14/2025 has been entered. The species elections has been maintained. The species of JAK2 V617F, CALR type I, and MPL W515K in the reply filed on 6/22/2021 and 10/27/2021 is acknowledged. Claims 1-7,9-16,18- 20,31 have been cancelled. Claims 8, 22, 29 are withdrawn as being drawn to a nonelected species. The following rejections for claims 17,21,23-28,30 are newly applied. This action is Nonfinal. Withdrawn Rejection The 35 USC 112a New Matter rejection made in the previous office action is withdrawn based upon amendments to the claims. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 17,21,23-28,30 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 17,21,23-28,30 are drawn to a diagnosing MPN based upon the presence of type 1 or type 2 mutations are detected. The claims are drawn to determination of type 1 and/or type 2 mutation is present wherein the calculated determinator value or 1 is higher than the cutoff value 1 and when the calculated determination of value 2 is lower than the predetermined cutoff value 2. The claims state that the predetermined cutoff value 1 is from an average value and standard deviation of determination value 1 and the predetermined cutoff value 2 is from an average value and standard deviation of determination value 2. The specification teaches that average values can be used as a threshold value using a particular formula (para 68). However, the specification does not provide that threshold value is the same as predetermined cutoff. Further, paragraph 68 is drawn to a plurality of values whereas it is not clear if the claims predetermined cutoff are determined with the sample or other specimens. The specification teaches in table 5 specific average values however it is not clear if the claims are intending to be limited to this value. However, the specification has not described the breadth of the claim language. Paragraph 15 probes that a formula and determination of gene mutation is present when value 1 is higher and value 2 is lower than a predetermined cutoff value. However, although the specification states this language it is not clear if this cutoff value is identical to a threshold value. Furthermore it is not clear how the average and standard deviation is measured when only one sample is detected. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 17,21,23-28,30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 17,21,23-28,30 are indefinite over “used for diagnosis” in the last line of claim 17. The phrase is indefinite as it is not clear how to perform the preamble of diagnosis with the steps of data analysis. By the term “used for” the claims can be interpreted as having non specified other steps to diagnosis. As such it is not clear the metes and bunds of diagnosis. Claims 17,21,23-28,30 are indefinite over the phrase “calculating a predetermined cutoff value 1 from an average value and standard deviation of determination value 1; calculating a predetermined cutoff value 2 from an average value and standard deviations of determination of value 2” recited in claim 17. These steps are unclear as it is not clear what average or standard deviations are from. Determination value 1 is only required in one subject and as such it is not clear how an average or deviation is determined. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D SALMON whose telephone number is (571)272-3316. The examiner can normally be reached 9-530. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Cheng (Winston) Shen can be reached on 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE D SALMON/ Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Dec 23, 2019
Application Filed
Oct 27, 2021
Response Filed
Jan 11, 2022
Non-Final Rejection — §112
Mar 14, 2022
Applicant Interview (Telephonic)
Mar 15, 2022
Non-Final Rejection — §112
Jun 21, 2022
Response Filed
Jul 13, 2022
Final Rejection — §112
Oct 17, 2022
Response after Non-Final Action
Nov 09, 2022
Request for Continued Examination
Nov 11, 2022
Response after Non-Final Action
Mar 06, 2023
Non-Final Rejection — §112
Aug 03, 2023
Response Filed
Oct 03, 2023
Final Rejection — §112
Mar 11, 2024
Request for Continued Examination
Mar 13, 2024
Response after Non-Final Action
Jun 25, 2024
Non-Final Rejection — §112
Oct 25, 2024
Response Filed
Jan 10, 2025
Final Rejection — §112
Apr 17, 2025
Examiner Interview Summary
Apr 17, 2025
Applicant Interview (Telephonic)
May 08, 2025
Response after Non-Final Action
Jul 14, 2025
Request for Continued Examination
Jul 17, 2025
Response after Non-Final Action
Mar 08, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601014
MULTIPLE KASP MARKER PRIMER SET FOR WHEAT PLANT HEIGHT MAJOR GENES AND USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12590324
COMPOSITIONS AND METHODS FOR TEMPLATE-FREE GEOMETRIC ENZYMATIC NUCLEIC ACID SYNTHESIS
2y 5m to grant Granted Mar 31, 2026
Patent 12577614
KITS AND METHODS FOR DETERMINING COPY NUMBER OF MOUSE TCR GENE
2y 5m to grant Granted Mar 17, 2026
Patent 12571056
METHOD AND KIT FOR THE IDENTIFICATION OF VACCINIUM MYRTILLUS
2y 5m to grant Granted Mar 10, 2026
Patent 12571027
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

8-9
Expected OA Rounds
42%
Grant Probability
80%
With Interview (+38.0%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 776 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month